The combining precision therapies with radiotherapy, in the field of oncology, has emerged as a promising approach to enhance the efficacy of cancer therapy.In the treatment of advanced stage NSCLC (NSCLC), osimertinib, a third gen EGFR TKI (TKI), has demonstrated remarkable efficacy.Concurrent osimertinib and radiotherapy, in which both treatments are administered concurrently, has been attracting attention for its potential to synergistically enhance patient results.The aim of this article is to explore the reason for combining osimertinib with concurrent radiotherapy, to discuss the challenges faced in it, and to emphasize the…
